Standardized Pathology Report for Colorectal Cancer, 2nd Edition
暂无分享,去创建一个
An Na Seo | Hee Kyung Chang | Hyo Jeong Kang | Gyeong Hoon Kang | Dong Wook Kang | D. Park | E. Yu | H. Lee | G. Kang | D. Kang | I. Do | J. Sohn | M. Chang | Y. Kang | H. Chang | Youn Wha Kim | J. H. Kim | S. Jin | A. Seo | Joon-Mee Kim | B. Kim | H. Han | M. Cho | Hee Jin Chang | Jeong Mo Bae | Hye Seung Han | Do Youn Park | Yun Kyung Kang | Hye Seung Lee | Eunsil Yu | Jung Ho Kim | J. Bae | H. Kang | In-Gu Do | Baek-hui Kim | Joon Mee Kim | Ho Sung Park | Kyung-Hwa Lee | Mee Yon Cho | Jin Hee Sohn | Mee Soo Chang | Eun Sun Jung | So-Young Jin | E. Jung | Ho-Sung Park | Kyung-Hwa Lee | Hee-kyung Chang
[1] D. Sargent,et al. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer , 2017, Journal of the National Cancer Institute.
[2] 김우호,et al. A Standardized Pathology Report for Colorectal Cancer , 2006 .
[3] E. Sabo,et al. Epidermal Growth Factor Receptor, c-MET, β-Catenin, and p53 Expression as Prognostic Indicators in Stage II Colon Cancer , 2004, Clinical Cancer Research.
[4] M. Pollheimer,et al. Intramural and extramural vascular invasion in colorectal cancer , 2012, Cancer.
[5] G Milano,et al. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] F. Marincola,et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.
[7] Shuji Ogino,et al. Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer , 2005, Clinical Cancer Research.
[8] F. Marincola,et al. Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.
[9] Z. Trajanoski,et al. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. , 2016, Immunity.
[10] M. Pino,et al. Microsatellite instability in the management of colorectal cancer , 2011, Expert review of gastroenterology & hepatology.
[11] L. Reggiani Bonetti,et al. Prognostic significance of grading based on the counting of poorly differentiated clusters in colorectal mucinous adenocarcinoma. , 2015, Human pathology.
[12] P. Lønning,et al. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases , 2016, International journal of cancer.
[13] I. Nagtegaal,et al. Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions , 2013, Endoscopy.
[14] R. Riddell,et al. Tumor budding in colorectal carcinoma: time to take notice , 2012, Modern Pathology.
[15] J. Park,et al. What Is the Ideal Tumor Regression Grading System in Rectal Cancer Patients after Preoperative Chemoradiotherapy? , 2015, Cancer research and treatment : official journal of Korean Cancer Association.
[16] J. Desai,et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.
[17] S Srivastava,et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.
[18] Ajay Goel,et al. Microsatellite instability in colorectal cancer. , 2010, Gastroenterology.
[19] J. Skibber,et al. Clinical Significance of Acellular Mucin in Rectal Adenocarcinoma Patients With a Pathologic Complete Response to Preoperative Chemoradiation , 2010, Annals of surgery.
[20] N. Goldstein,et al. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma , 2001, Cancer.
[21] Seung-Yong Jeong,et al. Indications for Subsequent Surgery After Endoscopic Resection of Submucosally Invasive Colorectal Carcinomas: A Prospective Cohort Study , 2009, Diseases of the colon and rectum.
[22] D. Berger,et al. Perineural invasion in cancer , 2009, Cancer.
[23] M. Schwartz,et al. Colorectal adenocarcinoma with micropapillary pattern and its association with lymph node metastasis , 2007, Modern Pathology.
[24] H. McLeod,et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. , 2002, European journal of cancer.
[25] Hidetaka Mochizuki,et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. , 2004, Gastroenterology.
[26] D. Berger,et al. Perineural invasion is an independent predictor of outcome in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Tabernero,et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.
[28] B. Leggett,et al. Sessile serrated adenomas with dysplasia: morphological patterns and correlations with MLH1 immunohistochemistry , 2017, Modern Pathology.
[29] J. H. Kim,et al. Prevalence and clinical significance of cellular and acellular mucin in patients with locally advanced mucinous rectal cancer who underwent preoperative chemoradiotherapy followed by radical surgery , 2016, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[30] B. Molnár,et al. Serrated pathway: alternative route to colorectal cancer. , 2013, World journal of gastroenterology.
[31] C. Gutschow,et al. Evaluation of histological regression grading systems in the neoadjuvant therapy of rectal cancer , 2012, International Journal of Colorectal Disease.
[32] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] A. Liakka,et al. Morphology and microsatellite instability in sporadic serrated and non‐serrated colorectal cancer , 2005, The Journal of pathology.
[34] Y. Nakanishi,et al. Clinicopathological significance of microscopic abscess formation at the invasive margin of advanced low rectal cancer , 2007, The British journal of surgery.
[35] Joanna A Gibson,et al. Pathology of premalignant colorectal neoplasia , 2016, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.
[36] A. Mattia,et al. A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome , 2017, Modern Pathology.
[37] D. Treanor,et al. Pathological response following long‐course neoadjuvant chemoradiotherapy for locally advanced rectal cancer , 2005, Histopathology.
[38] J. Jass,et al. A NEW PROGNOSTIC CLASSIFICATION OF RECTAL CANCER , 1987, The Lancet.
[39] D. Sargent,et al. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials , 2017, JAMA oncology.
[40] Bert Vogelstein,et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.
[41] R. Labianca,et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Wendy Frankel,et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. , 2009, Archives of pathology & laboratory medicine.
[44] A. Krasinskas. EGFR Signaling in Colorectal Carcinoma , 2011, Pathology research international.
[45] J. O’Sullivan,et al. Tumor Budding is a Strong and Reproducible Prognostic Marker in T3N0 Colorectal Cancer , 2009, The American journal of surgical pathology.
[46] H. Lee,et al. Colorectal micropapillary carcinomas are associated with poor prognosis and enriched in markers of stem cells , 2013, Modern Pathology.
[47] O. Dworak,et al. Pathological features of rectal cancer after preoperative radiochemotherapy , 1997, International Journal of Colorectal Disease.
[48] X. Puig,et al. Clinicopathological and molecular characterization of colorectal micropapillary carcinoma , 2011, Modern Pathology.
[49] E. Dogliotti,et al. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. , 2010, European journal of cancer.
[50] A. Zaitoun,et al. Prognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancer. , 2011, European journal of cancer.
[51] N. Shepherd,et al. Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) ‐ Pathology Standards and Datasets , 2017, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[52] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] C. Boland,et al. An Optimized Pentaplex PCR for Detecting DNA Mismatch Repair-Deficient Colorectal Cancers , 2010, PloS one.
[54] I. Mihaylova,et al. Degree of tumor regression after preoperative chemo-radiotherapy in locally advanced rectal cancer-Preliminary results. , 2011, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.
[55] N. Shepherd,et al. UK guidance for the pathological reporting of serrated lesions of the colorectum , 2015, Journal of Clinical Pathology.
[56] M. Mäkinen,et al. Colorectal serrated adenocarcinoma , 2007, Histopathology.
[57] J Ricke,et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[58] Robyn L. Temple-Smolkin,et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. , 2017, Archives of pathology & laboratory medicine.
[59] R. Haggitt,et al. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. , 1985, Gastroenterology.
[60] D. Schaid,et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. , 2003, Cancer research.
[61] J. Galon,et al. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. , 2016, International immunology.
[62] Claudia Maggi,et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. , 2015, European journal of cancer.
[63] Robyn L. Temple-Smolkin,et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] S. Serra,et al. Traditional serrated adenomas (TSAs) admixed with other serrated (so-called precursor) polyps and conventional adenomas: a frequent occurrence , 2015, Journal of Clinical Pathology.
[65] Sudhir Srivastava,et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.
[66] C. Belda-Iniesta,et al. EGFR and colon cancer: a clinical view , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[67] M. Kurrer,et al. Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer , 2012, Modern Pathology.
[68] Clinicopathological significance of Ki67 expression in colorectal cancer , 2020, Medicine.
[69] P. Laird,et al. Association between molecular subtypes of colorectal cancer and patient survival. , 2015, Gastroenterology.
[70] I. Nagtegaal,et al. Morphological changes in tumour type after radiotherapy are accompanied by changes in gene expression profile but not in clinical behaviour , 2004, The Journal of pathology.
[71] S. Groshen,et al. Molecular determinants of cetuximab efficacy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] F. Offner,et al. Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study , 2015, Virchows Archiv.
[73] R. Nozaki,et al. Management of early invasive colorectal cancer , 1995, Diseases of the colon and rectum.
[74] F. Bosman,et al. WHO Classification of Tumours of the Digestive System , 2010 .
[75] K. Song,et al. A Standardized Pathology Report for Gastric Cancer , 2005 .
[76] Colin C Pritchard,et al. Colorectal cancer molecular biology moves into clinical practice , 2010, Gut.
[77] H. Nassar. Carcinomas with Micropapillary Morphology: Clinical Significance and Current Concepts , 2004, Advances in anatomic pathology.
[78] K. Jakubowska,et al. Invasive micropapillary component and its clinico-histopathological significance in patients with colorectal cancer. , 2016, Oncology letters.
[79] E. Sabo,et al. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.
[80] J. Petiot,et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.
[81] Zongguang Zhou,et al. K-Ras mutation and prognosis of colorectal cancer: a meta-analysis. , 2015, Hepato-gastroenterology.
[82] Phil Quirke,et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016 , 2017, Modern Pathology.
[83] W. Samowitz. Evaluation of colorectal cancers for Lynch syndrome: practical molecular diagnostics for surgical pathologists , 2015, Modern Pathology.
[84] Toshihide Kumamoto,et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study , 2004, Journal of Gastroenterology.
[85] R. Riddell,et al. Cytokeratin‐based assessment of tumour budding in colorectal cancer: analysis in stage II patients and prospective diagnostic experience , 2017, The journal of pathology. Clinical research.
[86] D. Sargent,et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. , 2015, Gastroenterology.
[87] A. Rogers,et al. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy , 2014, Modern Pathology.
[88] M. Rugge,et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection , 2015, British Journal of Cancer.
[89] B. Memon,et al. Outcome of acutely perforated colorectal cancers: experience of a single district general hospital. , 2006, Surgical oncology.
[90] Iris D. Nagtegaal,et al. The Importance of the Pathologist’s Role in Assessment of the Quality of the Mesorectum , 2012, Current Colorectal Cancer Reports.
[91] E. Friedman,et al. Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] D. McMillan,et al. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. , 2012, Cancer treatment reviews.
[93] R. Yantiss,et al. Histologic Features and Cytologic Techniques That Aid Pathologic Stage Assessment of Colonic Adenocarcinoma , 2013, The American journal of surgical pathology.
[94] M. Kojima,et al. Intramucosal colorectal carcinoma with invasion of the lamina propria: a study by the Japanese Society for Cancer of the Colon and Rectum. , 2017, Human pathology.
[95] C. Eng,et al. The current landscape of locally advanced rectal cancer , 2011, Nature Reviews Clinical Oncology.
[96] April Fritz,et al. International Classification of Diseases for Oncology: ICD-0. , 2000 .
[97] M. Lai,et al. Micropapillary Component in Colorectal Carcinoma is Associated With Lymph Node Metastasis in T1 and T2 Stages and Decreased Survival Time in TNM Stages I and II , 2009, The American journal of surgical pathology.
[98] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[99] E. Rullier,et al. Prise en charge des cancers du rectum localement avancés : quel rôle pour le pathologiste en 2011 ? , 2011 .
[100] W. Samowitz,et al. Microsatellite instability and colorectal cancer. , 2011, Archives of pathology & laboratory medicine.
[101] Charles J. Kahi,et al. Serrated Lesions of the Colorectum: Review and Recommendations From an Expert Panel , 2012, The American Journal of Gastroenterology.